Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,397 across all filing types
Latest filing 2019-12-02 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
BLOCK LISTING INTERIM REVIEW
Regulatory Filings
2019-12-02 English
TOTAL VOTING RIGHTS
Regulatory Filings
2019-12-02 English
Block listing Interim Review
Regulatory Filings Classification · 98% confidence The document is a 'Block Listing Six Monthly Return' filed by AstraZeneca PLC via the London Stock Exchange's RNS (Regulatory News Service). This filing reports on the issuance of shares under specific employee share option schemes over a six-month period. It details the balance of unallotted securities, increases, and actual issuances. This type of regulatory disclosure regarding share capital changes and block listings falls under the 'Share Issue/Capital Change' category.
2019-12-02 English
Total Voting Rights
Regulatory Filings Classification · 98% confidence The document explicitly starts with an 'RNS Number' and is dated '02 December 2019'. The content discusses 'Voting Rights and Capital' and provides the total number of voting rights as of a specific date (30 November 2019), referencing the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. This type of mandatory regulatory disclosure regarding the total number of shares with voting rights is a standard regulatory announcement. Since it is a general regulatory announcement provided via RNS, and it doesn't fit the specific criteria for Director's Dealing (DIRS), Major Shareholding Notification (MRQ), or Share Issue (SHA), the most appropriate general classification is Regulatory Filings (RNS). The document length is short (3136 chars), but the content is a specific regulatory disclosure, not just an announcement *about* another report, making RNS a better fit than RPA.
2019-12-02 English
IMFINZI GRANTED FDA PRIORITY REVIEW FOR THE TREATMENT OF PATIENTS WITH EXTENSIVE
Regulatory Filings
2019-11-29 English
Imfinzi granted FDA Priority Review for SCLC
Earnings Release Classification · 99% confidence The document begins with 'RNS Number : 1178V' and is dated November 29, 2019. It announces regulatory news regarding an FDA decision (Priority Review for Imfinzi) and includes extensive details about clinical trials and company background. The presence of the RNS identifier and the nature of the announcement (a specific, time-sensitive corporate update not fitting other specific categories like 10-K, ER, or DIV) strongly suggests it is a general regulatory announcement. Since it is a formal announcement distributed via the RNS system, the most appropriate classification is Regulatory Filings (RNS), as it serves as the primary channel for such news releases to the market. Q4 2019
2019-11-29 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.